Excalibur Fund Manager
A €247 million fund fully committed to European human healthcare companies.
 | Amura Ltd Structure based drug design Secondary sale in February 2005 |
 | Ardana plc Drugs for reproductive disorders and hormone sensitive cancers IPO in March 2005 |
 | Ark Therapeutics Group plc Gene-based drugs for vascular and circulatory diseases and cancer IPO in March 2004 |
 | Biovertis AG Hospital-acquired infections; respiratory tract infections; urinary tract infections Acquired Morphochem AG in March 2006 |
 | Biovex Group Inc Development and commercialisation of biological treatments for cancer and the prevention of infectious disease |
 | Cambridge Biotechnology Ltd Small molecule drugs for pain and obesity Aquired by Biovitrum AB in April 2005 |
 | Cyclacel Pharmaceutical Inc Cell cycle control drugs for cancer IPO in January 2006 |
 | De Novo Pharmaceuticals Ltd In silico structure-based drug design |
 | Emergent BioSolutions Inc Research, development and manufacture of novel vaccines and related products IPO in November 2006. Fully disposed |
 | EpiCept Inc Topical pain management IPO in January 2006 |
 | Intercytex Group plc Hair and tissue regrowth IPO in February 2006 |
 | LiDCO Group plc Cardiac output monitors IPO in June 2004 |
 | Neurotech Inc Cell-based drugs for diseases of the eye |
 | Noxxon Pharma AG Mirror image oligonucleotide drugs |
 | Onyvax Ltd Whole-cell allogenic vaccines for cancer |
 | PanTherix Ltd Novel broad-spectrum antibiotics |
 | Paradigm Therapeutics Ltd Drug discovery platform company Acquired by Takeda Pharmaceutical Company Ltd in December 2004 |
 | ReNeuron Group plc Treatments for neurological disorders IPO in August 2005 |
 | Santhera Pharmaceuticals AG Small molecule therapeutics for neuromuscular and metabolic diseases IPO in November 2006 |
 | Sosei Co. Ltd Identifying new uses for established drugs Arakis merged with Sosei Co in August 2005 |
 | Vectura Group plc Drug formulations and devices for respiratory diseases IPO in July 2004 |
 | Wilex AG Antibody and small molecule cancer therapies IPO in November 2006 |
 | XTL Biopharmaceuticals plc Monoclonal antibody and small molecule therapeutics for Hepatitis IPO in September 2000. Fully disposed |
